McDermott Advises ILIFE Consulting on its Acquisition by Comac Medical Group | McDermott

McDermott Advises ILIFE Consulting on its Acquisition by Comac Medical Group

Overview


McDermott Will & Emery advised ILIFE Consulting, a contract research organization company (CRO) specializing in the early-stage development of oncology and biotechnology products, on its acquisition by Comac Medical Group, one of the leading pan-European CRO platforms and a preferred partner of small and mid-sized biopharmaceutical companies around the world.

In connection with this transaction, Comac Medical Group was supported by EdgeCap Partners.

ILIFE’s integration into the Group will enable complementary expertise and reach, including enhanced capabilities in biostatistics, data management, pharmacovigilance, bioanalytical services, and Comac Medical’s state-of-the-art Early Phase Clinical Research Unit.
The McDermott team involved in this transaction included:

Life Sciences

Tax

About McDermott


McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.